13G Filing: Kerrisdale Capital and Adamas Pharmaceuticals Inc (ADMS)

Adamas Pharmaceuticals Inc (NASDAQ:ADMS): Sahm Adrangi’s Kerrisdale Capital filed an amended 13D.

You can check out Kerrisdale Capital’s latest holdings and filings here.

Please follow Kerrisdale Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Kerrisdale Capital or update its stock holdings.

Sahm Adrangi
Sahm Adrangi
Kerrisdale Capital

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Kerrisdale Partners Master Fund Ltd 1,473,247 0 1,473,247 0 1,473,247 6.5%
Kerrisdale Advisers 0 1,473,247 0 1,473,247 1,473,247 6.5%
Sahm Adrangi 0 1,473,247 0 1,473,247 1,473,247 6.5%
Sahm Adrangi
Sahm Adrangi
Kerrisdale Capital

Page 1 of 7 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No.     )

 

 

ADAMAS
PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

00548A106

(CUSIP Number)

October 24, 2017

(Date of Event Which Requires Filing of this Statement)

 

 

Check the
appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)


Rule 13d-1(d)

Follow Adamas Pharmaceuticals Inc (NASDAQ:ADMS)